Sutro Biopharma


Analyst and Investor Conference Call April 27, 2020

NASDAQ: STRO Bill Newell, CEO



Forward Looking Statements

- This presentation and the accompanying oral presentation contain "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our future financial performance, business plans and objectives, current and future clinical and preclinical activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, timing and success of our planned development activities, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, potential growth opportunities, financing plans, competitive position, industry environment and potential market opportunities.
- Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors, including risks and uncertainties related to our cash forecasts, our and our collaborators' ability to advance our product candidates, the receipt and timing of potential regulatory submissions, designations, approvals and commercialization of product candidates, the timing and results of preclinical and clinical trials, and the expected impact of the COVID-19 pandemic on our operations. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. These factors, together with those that may be described in greater detail under the heading "Risk Factors" contained in our most recent Annual Report on Form 10-K and other reports the company files from time to time with the Securities and Exchange Commission, may cause our actual results, performance or achievements to differ materially from those anticipated or implied by our forward-looking statements.
- You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. Moreover, neither we nor our management assume responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to publicly update any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations, except as required by law.
- This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.
- Solely for convenience, the trademarks and tradenames referred to in this presentation appear without the ® and [™] symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames.



STRO-002-GM1, a First in Human, Phase 1 study of STRO-002, an anti-Folate Receptor-alpha (FRα) Antibody Drug Conjugate, in Patients with Advanced Platinum Resistant/Refractory Epithelial Ovarian Cancer, including Fallopian Tube or Primary Peritoneal Cancers


R. Wendel Naumann, Denise Uyar, John W. Moroney, Fadi S. Braiteh, Russell J. Schilder, John P. Diaz, Erika Hamilton, Sami Diab, Lainie P. Martin, David M. O'Malley, Richard T. Penson, Clifford DiLea, Michael Palumbo, Venita De Almeida, Shannon Matheny, Arturo Molina.



STRO-002-GM1, Phase 1 Study was Initiated in March 2019

Key Inclusion: Advanced platinum-resistant/refractory disease; patients are not selected for FRα expression (all comers)

Key Exclusion: Prior FolRα targeting ADC, low grade ovarian carcinoma, clinically significant pre-existing ocular disorders



Part 1: Safety, MTD, RP2D, PK, ADA, preliminary efficacy

Part 2: Response rates, duration of response, PFS (RECIST 1.1), safety, PK




CONFIDENTIAL


Patient Demographics and Disease Characteristics Reported April 27, 2020 (Data as of April 20, 2020)

Characteristic	Total N = 30 (%)			
Age, median (range), years	60.5 (47-76)			
Tumor type				
EOC	25 (83)			
Fallopian tube	3 (10)			
Primary peritoneal	2 (7)			
ECOG PS				
0	17 (57)			
1	13 (43)			
Madian (inc. fram. dia manaia (nam. a)	2.0.100 m $(0.6, 17.1)$			
Median time from diagnosis (range)	3.9 years (0.6- 17.1)			
Median time from diagnosis (range) Median lines of prior therapy (range)	5 (2-10)			
Median lines of prior therapy (range)	5 (2-10)			
Median lines of prior therapy (range) Platinum	5 (2-10) 30 (100)			
Median lines of prior therapy (range) Platinum ≥ 3 prior platinum regimens	5 (2-10) 30 (100) 12 (40)			
Median lines of prior therapy (range) Platinum ≥ 3 prior platinum regimens Taxanes	5 (2-10) 30 (100) 12 (40) 29 (97)			
Median lines of prior therapy (range)Platinum≥ 3 prior platinum regimensTaxanesBevacizumab	5 (2-10) 30 (100) 12 (40) 29 (97) 23 (77)			


Characteristic	Total N = 30 (%)		
Dose Level of STRO-002			
0.5 mg/kg, 1.0 mg/kg, 1.8 mg/kg	5 (17)		
2.9 mg/kg	3 (10)		
4.2 mg/kg	3 (10)		
5.2 mg/kg	6 (20)		
5.6 mg/kg	3 (10)		
6.0 mg/kg	9 (30)		
6.4 mg/kg	1 (3)		

62% (13/21) of Patients Treated at ≥ 2.9 mg/kg with Post-baseline Assessments Have ≥ 50% Reduction or Normalization of CA-125





35% (7/20) Patients Evaluable for Progression at ≥ 2.9 mg/kg Remained on Study > 24 weeks



Duration calculated as time to PD from 1st dose or according to doses received (2 doses = 3 weeks, 3 doses= 6 weeks, etc.)



CONFIDENTIAL

75% (15/20*) of Patients Treated at ≥ 2.9 mg/kg Have Initial Post-Baseline Scans Showing Stable Disease or Partial Response

2.9 mg/kg 4.3 mg/kg 5.2 mg/kg 5.6 mg/kg *5 ongoing patients 6.0 mg/kg 6.4 mg/kg have not reached first post-baseline \Rightarrow On study scan timepoint Unconfirmed SD Confirmed SD Unconfirmed PR Confirmed PR PD (RECIST or UCP)

Data as of 20 Apr 2020



CONFIDENTIAL

30


40

50

20

10

All Patients with CA-125 ≥ 50% Reduction or Normalization Remain on Study Treatment and 12/12 (100%) Achieved Tumor Control



* Patient has not yet reached first RECIST scan timepoint Data as of 20 Apr 2020



Treatment Emergent AEs in ≥ 20% of Patients (without causality attribution)

- The emerging STRO-002 safety profile includes mostly mild adverse events 89% of all AEs reported are grade 1 or 2.
- 2 DLTs have been reported: neuropathy (6.0 mg/kg); bone pain (6.4 mg/kg)

Treatment Emergent Adverse Events (TEAE)							
TEAE >20%	Grade 1	Grade 2	Grade 3	Grade 4*	N= 29 (%)		
Fatigue	7 (24)	10 (35)	2 (7)		19 (66)		
Nausea	13 (45)	4 (14)			17 (59)		
Neutropenia/ Neutrophil count decreased			6 (21)	6 (21)	12 (41)		
Constipation	6 (21)	6 (21)			12 (41)		
Arthralgia	3 (10)	5 (17)	4 (14)		12 (41)		
Abdominal pain	5 (17)	2 (7)	3 (10)		10 (35)		
Decreased appetite	7 (24)	3 (10)			10 (35)		
Vomiting	6 (21)	3 (10)			9 (31)		
AST increased	8 (28)	1 (3)			9 (31)		
Dizziness	6 (21)	2 (7)			8 (28)		
Diarrhea	5 (17)	1 (3)	1 (3)		7 (24)		
Peripheral neuropathy	2 (7)	4 (14)	1 (3)		7 (24)		
Headache	5 (17)	1 (3)			6 (21)		
Myalgia	3 (10)	2 (7)	1 (3)		6 (21)		

*No other grade 4 events have been reported N=29 as one patient has not reported any AEs Data as of 20 Apr 2020



STRO-002 Emerging Safety Profile, Evidence of Anti-tumor Activity and Clinical Benefit are Encouraging – AACR April 27, 2020

62% (13/21)	Patients at 2.9 mg/kg or higher with post baseline assessments have had a ≥ 50% reduction in CA-125 levels or normalization of CA-125
75% (15/20)	Patients at 2.9 mg/kg or higher with at least 1 post baseline scan showing stable disease or a PR
	 6 of the 15 were confirmed at a subsequent scan 7 patients (at 5.2 mg/kg or higher) with initial stable disease are awaiting follow-up assessments
100% (12/12)	All evaluable patients with CA-125 ≥ 50% reduction or normalization remain on study treatment and achieved tumor control

- 89% of all AEs reported are grade 1 or 2
- Prophylactic corticosteroid eye drops are not required

Summary - Well Tolerated, Encouraging Clinical Benefit Expansion Cohorts Planned for 2H20

STRO-002 was generally well tolerated and mostly associated with mild events

- 89% of all AEs reported are grade 1 or 2
- Prophylactic corticosteroid eye drops have not been required
- MTD has not been reached, additional patients are being enrolled in the 5.2mg/kg 6.0mg/kg range to better characterize RP2D

Follow-up is still early and enrollment ongoing

• 5/30 = 17% have not had post-treatment scan for initial RECIST assessment

Next Steps:

- Recommended Phase 2 dose to be confirmed
- Expansion cohorts to be initiated



Thank You to the Patients, their Families and our Participating Study Site Investigators and Staff

Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC

Medical College of Wisconsin, Milwaukee, WI

University of Chicago, Chicago, IL

Comprehensive Cancer Centers of Nevada, Las Vegas, NV

Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA

Miami Cancer Institute at Baptist Health, Miami, FL

Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville, TN

Rocky Mountain Cancer Center, Aurora, CO

University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA

Ohio State University, Wexner Medical Center, Columbus, OH

Massachusetts General Hospital, Boston, MA

Sutro Biopharma

Analyst and Investor Conference Call April 27, 2020

NASDAQ: STRO Bill Newell, CEO

